SESSION TITLE: Safety and Effectiveness of COPD Treatments
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Tuesday, October 25, 2016 at 11:00 AM - 12:15 PM
PURPOSE: There is a growing body of research supporting initiating long-acting β-agonist (LABA) therapy via small volume nebulization (SVN) in patients with uncontrolled COPD. Arformoterol SVN compared to a placebo has previously demonstrated a 40% lower risk of respiratory death or COPD-related hospitalization over 1 year, improvements in trough FEV1 and FVC, and improved quality of life via the St. George’s Hospital Respiratory Questionnaire and Clinical COPD Questionnaire.1 Arformoterol SVN has also shown to be superior as compared to short-acting β-agonist (SABA) SVN in preventing readmissions after hospitalization for COPD exacerbation.2 In patients with uncontrolled COPD, despite regular use of a combination LABA/corticosteroid (CS) inhaler, changing the medication delivery system to an SVN formulation is an option for better disease control. Hypothesized reasons for improved disease control with SVN formulations include ease of use and improved medication delivery. There is currently no data comparing inhaled LABA/CS versus the same medication via SVN.